CG Oncology (CGON) Net Cash Flow (2023 - 2026)

CG Oncology has reported Net Cash Flow for 4 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 100.58% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$7.7 million (up 78.53% YoY), and the FY2025 full-year result was -$224.6 million, down 190.26% from the prior year.
• Net Cash Flow for Q1 2026 stood at $1.3 million, up from -$12.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $213.7 million in Q4 2024, with the low at -$215.6 million in Q1 2025.
• Historically, Net Cash Flow has averaged -$4.2 million across 4 years, with a median of -$2.0 million in 2023.
• Annual changes were most pronounced in 2024 — Net Cash Flow soared 10745.59% — and 2025, when it plunged 411.55%.
• CG Oncology's Net Cash Flow stood at -$2.0 million in 2023, then soared by 10745.59% to $213.7 million in 2024, then slumped by 105.94% to -$12.7 million in 2025, then soared by 109.88% to $1.3 million in 2026.
• The last three Net Cash Flow figures came in at $1.3 million (Q1 2026), -$12.7 million (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.